Benralizumab
- PDF / 169,235 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 13 Downloads / 132 Views
1 S
Development of resistance (late-occurring unresponsiveness) in asthma: case report A 66-year-old patient [sex not stated] showed development of resistance (late-occurring unresponsiveness) on benralizumab treatment for asthma. The patient was initially treated with benralizumab [dosage and route not stated] resulting in significantly improvement of asthma symptoms and decreased peripheral eosinophil count. The patient’s unspecified oral steroids were also discontinued. However, after 7 months of benralizumab treatment, the patient’s asthma worsened with an increase in peripheral eosinophil count. The patient’s asthma was complicated by development of eosinophilic chronic rhinosinusitis. It was considered that development of neutralizing antibodies to benralizumab might have resulted in eosinophilic inflammation causing recurrence of asthma symptoms (late-occurring unresponsiveness/ development of resistance). The patient’s benralizumab was switched to mepolizumab leading to an improvement in nasal symptoms. Matsumoto-Sasaki M, et al. A case of severe asthma switched to mepolizumab due to late-occurring unresponsiveness to benralizumab. [Japanese]. Arerugi 69: 678-682, No. 803516287 8, 2020. Available from: URL: http://doi.org/10.15036/arerugi.69.678 [Japanese; summarised from an abstract]
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
